Progress of fixed-cycle therapy and continuous therapy in multiple myeloma / 白血病·淋巴瘤

Multiple myeloma (MM) accounts for 13％of hematological malignancies, which often happens in elderly patients. The introduction of new drugs and treatments has improved the patients'survival time significantly, but some patients may relapse at different stages of treatment. Some studies have demonstrated that lenalidomide, bortezomib or bortezomib combination regimen could improve progression-free survival (PFS) in the patients at standard risk or at high risk. In patients who are not suitable for transplantation, patients treated with lenalidomide plus dexamethasone regimen consistently have longer survival time than those treated with fixed-cycle melphalan plus prednisone, thalidomide regimen, so the optimal treatment is the appropriate choice. This article reviews the efficacy of fixed-cycle therapy and continuous therapy for post-transplant and non-transplant patients.

Clinical Observation of Mifepristone Cycle Therapy in the Treatment of Perimenopausal Dysfunctional Uter-ine Bleeding / 中国药房

OBJECTIVE:To observe the efficacy and safety of mifepristone cycle therapy in the treatment of perimenopausal dysfunctional uterine bleeding. METHODS:Totally 116 patients with perimenopausal dysfunctional uterine bleeding were randomly divided into control group and observation group. Control group was given Mifepristone tablet 10 mg from 3 d after diagnostic cu-rettage on an empty stomach for continuous 90 d,once a day. Observation group was given Mifepristone tablet 10 mg from 3 d af-ter diagnostic curettage on an empty stomach,once a day,and it was stopped after continuous 5 d. Then it continued 5 d from the first day of menstruation,and lasted 3 menstrual cycles. The clinic data was observed,including clinical efficacy,estradiol(E2),fol-licle-stimulating hormone (FSH),luteinizing hormone (LH),progesterone (P),hemoglobin (Hb),endometrial thickness,men-strual conditions and recurrence in 2 groups before and after treatment were observed,and the incidence of adverse reactions were recorded. RESULTS:After treatment,E2,FSH,LH and P in 2 groups were significantly lower than before,and observation group was lower than control group,the differences were statistically significant(P0.05). Total effective rate in observation group significantly higher than control group,normal proportion of menstruation were significantly better than control group,the differences were statistically sig-nificant(P0.05). CONCLUSIONS:Mifepristone cycle therapy has significant efficacy in the treatment of perimenopausal dysfunctional uterine bleeding,can significantly improve the hormone level and the establishment of normal menstrual cycle and re-duce endometrial thickness,with good safety.